Loxapine inhalation powder (Adasuve, Teva), approved by the FDA on December 21, 2012, utilizes an antipsychotic with more than three decades of experience in a novel delivery system for the treatment of agitation associated with schizophrenia or bipolar mania.
From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash
A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.
Managed Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."